Archive for November, 2009

$112 million settlement: charged with kickbacks from drug company & recommending docs prescribe antipsychotic drug Risperdal

Wednesday, November 4th, 2009

Reuters
November 3, 2009

Omnicare Inc, the largest U.S. provider of pharmacy services to nursing homes, will pay $98 million and Teva subsidiary IVAX Pharmaceuticals will pay $14 million to settle allegations of kickbacks, the U.S. Department of Justice said on Tuesday.

The department said Omnicare both solicited and paid kickbacks.

Omnicare allegedly asked IVAX to pay $8 million in exchange for agreeing to purchase $50 million in IVAX drugs, the DOJ said.

It also accused Omnicare of soliciting kickbacks from Johnson & Johnson in exchange for recommending that physicians prescribe the antipsychotic drug Risperdal to nursing home patients.

“J&J’s kickbacks to Omnicare took multiple forms, including rebates that were conditioned on Omnicare engaging in an ‘Active Intervention Program’ for Risperdal and payments disguised as data purchase fees, educational grants, and fees to attend Omnicare meetings,” the Justice Department said.

Read entire article: http://www.reuters.com/article/healthcareSector/idUSN0350746820091103

« Return to news items


Share

Psychiatrist exposed in Grassley investigation resigns after failing to report hundreds of thousands in Pharma funds

Monday, November 2nd, 2009

Bob Grant
TheScientist.com
November 2, 2009

The Emory University psychiatry researcher who failed to report hundreds of thousands of dollars in pharmaceutical company payouts while receiving millions of dollars in funding from the National Institutes of Health to study the company’s anti-depressant drugs is leaving the university, according to the Atlanta Journal Constitution.

Charles Nemeroff,  a renowned depression researcher, failed to disclose to Emory approximately $800,000 in payments he received from drug maker GlaxoSmithKline (GSK) while he was the principal investigator (PI) on a multi-million dollar grant from the NIH to study five GSK antidepressants. Amid an investigation conducted by Emory, Nemeroff stepped down from his position as chairman of the psychiatry department last October. Later that month, the psychiatrist stepped down as PI from the $9.3 million NIH grant as the Senate probed his failure to disclose income from GSK, and the NIH froze funding on the five-year grant.

Read entire article: http://www.the-scientist.com/blog/display/56127/

« Return to news items


Share

Dr. Peter Breggin: Antipsychotic Drugs, Their Harmful Effects, and the Limits of Tort Reform

Monday, November 2nd, 2009

Dr. Peter Breggin
The Huffington Post
October 31, 2009

There are many problems within our legal system that could benefit from reform. But within the area in which I have great experience as a psychiatric expert, so-called tort reform has already gone too far. It is already too difficult for injured patients or their surviving families to bring malpractice suits against physicians and health facilities, and product liability suits against drug companies, even when their cases have great merit. I believe in private health care and I believe in the free market, but liberty requires checks and balances. The right to sue medical practitioners and pharmaceutical companies provides a necessary control in our free market system, as well as a means for individuals to seek compensation and justice.

Harm Caused by Antipsychotic Drugs

For illustrative purposes, I’ll focus on the newer antipsychotic drugs, the so-called atypicals, including Zyprexa, Risperdal, Geodon, Seroquel, and Abilify. These drugs produce horrendous adverse effects that often lead the victims or their surviving families to consider bringing lawsuits against doctors, health care facilities, or drug companies.

First, the antipsychotic drugs produce tardive dyskinesia. Tardive dyskinesia involves drug-induced abnormal movements that commonly disfigure patients and in some cases result in lifelong pain and total disability.

Read entire article: http://www.huffingtonpost.com/dr-peter-breggin/antipsychotic-drugs-their_b_341108.html

« Return to news items


Share

In UK, Doctors under fire as an alarming numbers of children are given drugs to combat depression and ADHD

Monday, November 2nd, 2009

Jenny Hope
Daily Mail
October 30, 2009

The number of prescriptions being given to children with hyperactivity, depression and other mental health problems has soared over two years, according to new figures.

Over 420,000 prescriptions were issued to children under 16 with attention deficit hyperactivity disorder (ADHD) in 2007 – up 33 per cent since 2005.

The number went up 51 per cent for youngsters aged 16-18, reaching 40,000 in 2007.

During this period NHS guidance endorsed at least three drugs for ADHD where other treatments have failed, despite fears about side effects and some critics complaining it medicalises antisocial behaviour.

More than 113,000 prescriptions of antidepressants were issued to children under 16 in 2007, a six per cent increase over two years.

Almost 108,000 antidepressant prescriptions went to 16-18-year-olds, which was unchanged over the period.

« Return to news items


Share